Compare DexCom, Inc. (DXCM) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs RLX Technology Inc — how do they compare? DexCom, Inc. trades at $77.44 (market cap $28.06B), while RLX Technology Inc trades at $2.03 (market cap $2.46B). The key difference: DexCom, Inc. is far larger — about 11.4× RLX Technology Inc's market cap, and RLX Technology Inc pays a 4.98% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RLX | |
|---|---|---|
Market Cap | $28.06B | $2.46B |
Sector | Health | Technology |
52-Week High | $89.53 | $2.73 |
52-Week Low | $54.84 | $1.79 |
Enterprise Value | $27.03B | $1.09B |
Dividend Yield | — | 4.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
RLX trades at $2.025, up 2.27% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth driven by international expansion, though it missed EPS estimates for three consecutive quarters. With a P/E of 18.37 and strong cash flow from operations of $1.10B in 2025, fundamentals show profitability but recent earnings underperformance warrants attention.
The outlook is mixed; RLX operates in a high-growth vaping market projected to reach $462bn by 2033, and it is debt-free with a cash-rich balance sheet. However, risks include regulatory pressures in China and consistent earnings misses. Analyst sentiment is neutral with a single hold rating, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
